These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27189164)

  • 21. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line.
    Biliran H; Wang Y; Banerjee S; Xu H; Heng H; Thakur A; Bollig A; Sarkar FH; Liao JD
    Clin Cancer Res; 2005 Aug; 11(16):6075-86. PubMed ID: 16115953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. β-Arrestins Regulate Stem Cell-Like Phenotype and Response to Chemotherapy in Bladder Cancer.
    Kallifatidis G; Smith DK; Morera DS; Gao J; Hennig MJ; Hoy JJ; Pearce RF; Dabke IR; Li J; Merseburger AS; Kuczyk MA; Lokeshwar VB; Lokeshwar BL
    Mol Cancer Ther; 2019 Apr; 18(4):801-811. PubMed ID: 30787175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive analysis of microRNA-messenger RNA regulatory network in gemcitabine-resistant bladder cancer cells.
    Zhang S; Chang YY; Gong YW; Gao YJ; Guo Q; Wang YH; Zhao YL; Wang ZP
    J Cell Biochem; 2019 Apr; 120(4):6347-6360. PubMed ID: 30304549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting HNRNPU to overcome cisplatin resistance in bladder cancer.
    Shi ZD; Hao L; Han XX; Wu ZX; Pang K; Dong Y; Qin JX; Wang GY; Zhang XM; Xia T; Liang Q; Zhao Y; Li R; Zhang SQ; Zhang JH; Chen JG; Wang GC; Chen ZS; Han CH
    Mol Cancer; 2022 Feb; 21(1):37. PubMed ID: 35130920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long noncoding RNA NORAD acts as a ceRNA mediates gemcitabine resistance in bladder cancer by sponging miR-155-5p to regulate WEE1 expression.
    Yang Y; Zhang G; Li J; Gong R; Wang Y; Qin Y; Ping Q; Hu L
    Pathol Res Pract; 2021 Dec; 228():153676. PubMed ID: 34753061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of immunohistochemistry-based molecular subtype on predicting chemotherapy response and survival in patients with T1 stage bladder cancer after bladder-preserving treatment.
    Lu J; Zhang Y; Wu C; Chu C; Liu Z; Cao Y
    Jpn J Clin Oncol; 2021 Mar; 51(3):424-433. PubMed ID: 33319245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression landscape of cancer-FOXP3 and its prognostic value in pancreatic adenocarcinoma.
    Gong R; Wang J; Xing Y; Wang J; Chen X; Lei K; Yu Q; Zhao C; Li S; Zhang Y; Wang H; Ren H
    Cancer Lett; 2024 May; 590():216838. PubMed ID: 38561039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer.
    Wang S; Zhang H; Scharadin TM; Zimmermann M; Hu B; Pan AW; Vinall R; Lin TY; Cimino G; Chain P; Vuyisich M; Gleasner C; Mcmurry K; Malfatti M; Turteltaub K; de Vere White R; Pan CX; Henderson PT
    PLoS One; 2016; 11(1):e0146256. PubMed ID: 26799320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143.
    An Q; Zhou L; Xu N
    Biomed Pharmacother; 2018 Jul; 103():415-420. PubMed ID: 29674277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MRE11A and SKP2 genes are associated with the increased cytotoxicity induced by the synergistic effects of cisplatin and gemcitabine in bladder cancer cells.
    da Silva GN; de Camargo EA; Sávio AL; Salvadori DM
    Mol Biol Rep; 2014 Jul; 41(7):4613-21. PubMed ID: 24652204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long non-coding RNA GHET1 contributes to chemotherapeutic resistance to Gemcitabine in bladder cancer.
    Li B; Xie D; Zhang H
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):187-194. PubMed ID: 31115606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ALDH1A3, the Major Aldehyde Dehydrogenase Isoform in Human Cholangiocarcinoma Cells, Affects Prognosis and Gemcitabine Resistance in Cholangiocarcinoma Patients.
    Chen MH; Weng JJ; Cheng CT; Wu RC; Huang SC; Wu CE; Chung YH; Liu CY; Chang MH; Chen MH; Chiang KC; Yeh TS; Su Y; Yeh CN
    Clin Cancer Res; 2016 Aug; 22(16):4225-35. PubMed ID: 27076629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity.
    Wahlin S; Boman K; Moran B; Nodin B; Gallagher WM; Karnevi E; Jirström K
    BMC Cancer; 2022 Feb; 22(1):131. PubMed ID: 35109796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Olive Mill Wastewater Inhibits Growth and Proliferation of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro by Down-Regulating the Akt/mTOR-Signaling Pathway.
    Rutz J; Maxeiner S; Juengel E; Chun FK; Tsaur I; Blaheta RA
    Nutrients; 2022 Jan; 14(2):. PubMed ID: 35057550
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Wei W; Sun J; Zhang H; Xiao X; Huang C; Wang L; Zhong H; Jiang Y; Zhang X; Jiang G
    Cancer Res; 2021 Dec; 81(24):6142-6156. PubMed ID: 34702726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Novel Long Non-Coding RNA KMU15 Promotes Growth and Chemoresistance of Bladder Cancer.
    Huang Y; Luan T; Bao X; Fu S; Li N; Li H; Wang H; Li C; Wang J
    Clin Lab; 2019 Dec; 65(12):. PubMed ID: 31850704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
    Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
    Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIF-1α-dependent miR-424 induction confers cisplatin resistance on bladder cancer cells through down-regulation of pro-apoptotic UNC5B and SIRT4.
    Yu M; Ozaki T; Sun D; Xing H; Wei B; An J; Yang J; Gao Y; Liu S; Kong C; Zhu Y
    J Exp Clin Cancer Res; 2020 Jun; 39(1):108. PubMed ID: 32522234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypoxia-elevated circELP3 contributes to bladder cancer progression and cisplatin resistance.
    Su Y; Yang W; Jiang N; Shi J; Chen L; Zhong G; Bi J; Dong W; Wang Q; Wang C; Lin T
    Int J Biol Sci; 2019; 15(2):441-452. PubMed ID: 30745833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
    Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
    Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.